Phaseline

Companies › Syntrix Biosystems

Syntrix Biosystems: clinical trials, targets and expected readouts

1 active drug program in 11 registered trials: 7 Phase 1, 4 Phase 2; Hematology, Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SX-682
Interleukin-8 receptors, CXCR1/CXCR2 inhibitor
CXCR2, CXCR1Phase 2Metastatic Castration-resistant Prostate Cancer; Melanoma Stage III; Myelodysplastic Syndromes; Metastatic Lung Non-Small Cell Carcinoma …Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04477343SX-682Phase 1Pancreatic Ductal AdenocarcinomaOncologyDec 2026
NCT06622005SX-682Phase 1Recurrent Multiple MyelomaOncologyApr 2027
NCT03161431SX-682Phase 1Melanoma Stage IIIOncologyJun 2027
NCT06228053SX-682Phase 2Metastatic Castration-resistant Prostate CancerOncologyJun 2027
NCT05570825SX-682Phase 2Metastatic Lung Non-Small Cell CarcinomaOncologyJul 2027
NCT06149481SX-682Phase 1Metastatic Colorectal CancerOncologyOct 2027
NCT05604560SX-682Phase 2Pancreatic CancerOncologyDec 2027
NCT04245397SX-682Phase 1Myelodysplastic SyndromesHematologyMar 2028
NCT07002320SX-682Phase 1Metastatic Castrate-Resistant Prostate Cancer (mCRPC)OncologyOct 2029
NCT07322341SX-682Phase 2Advanced Lung Non-Small Cell CarcinomaOncologyNov 2030
NCT07667400SX-682Phase 1Head and Neck CancerOncologyOct 2036

Targets

CXCR2 (1) CXCR1 (1)

Companies with the same targets

–

Companies built like this

Electra Therapeutics Servier Affaires Médicales Theravia Geron Shanghai Guangsheng Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.